Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemia
Open Access
- 1 January 2000
- journal article
- review article
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 105 (1), 3-7
- https://doi.org/10.1172/jci9083
Abstract
No abstract availableThis publication has 30 references indexed in Scilit:
- Phenylamino‐Pyrimidine (PAP) Derivatives: A New Class of Potent and Selective Inhibitors of Protein Kinase C (PKC)Archiv der Pharmazie, 1996
- Tyrosine Kinase Activity and Transformation Potency of bcr-abl Oncogene ProductsScience, 1990
- Induction of Chronic Myelogenous Leukemia in Mice by the P210
bcr/abl
Gene of the Philadelphia ChromosomeScience, 1990
- The Molecular Genetics of Philadelphia Chromosome–Positive LeukemiasThe New England Journal of Medicine, 1988
- Unique fusion of bcr and c-abl genes in Philadelphia chromosome positive acute lymphoblastic leukemiaCell, 1987
- The Chronic Myelogenous Leukemia-Specific P210 Protein Is the Product of the bcr / abl Hybrid GeneScience, 1986
- Fused transcript of abl and bcr genes in chronic myelogenous leukaemiaNature, 1985
- An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activityCell, 1984
- Translocation of c-abl oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemiaNature, 1983
- A New Consistent Chromosomal Abnormality in Chronic Myelogenous Leukaemia identified by Quinacrine Fluorescence and Giemsa StainingNature, 1973